

Calcitonin Gene-Related Peptide (CGRP) Inhibitors as Preventive Treatments for Patients with Episodic or Chronic Migraine: Effectiveness and Value

Key Stakeholder Organizations

ICER has identified the following organizations as key stakeholders for its review of CGRP inhibitors as preventive treatments for patients with episodic or chronic migraine. ICER has invited or received input from the following organizations, and welcomes suggestions from the broader community on additional organizations to add to this list. ICER also receives input from independent patients and clinicians, and invites the public to submit recommendations for key stakeholders in these categories. None of these individuals or organizations are responsible for the final contents of ICER’s report or should be assumed to support any part of the report, which is solely the work of the ICER team and its affiliated researchers.

For a complete list of key dates and opportunities for input on this project, please visit [ICER’s website](#).

- Academy of Managed Care Pharmacy
- Aetna, Inc.
- Allergan, plc.
- Alliance for Headache Disorders Advocacy
- Anthem, Inc.
- American Academy of Neurology
- American Chronic Pain Association
- American Headache Society
- American Migraine Foundation
- Amgen, Inc.
- Blue Shield of California
- California Department of Health Care Services
- Chronic Migraine Awareness, Inc.
- Cigna, Inc.
- Clusterbusters
- Coalition for Headache and Migraine Patients (CHAMP)
- Eli Lilly and Co.
- Global Healthy Living Foundation
- Headache and Migraine Policy Forum
- Health Net, Inc.
- Institute for Patient Access
- Kaiser Permanente
- Migraine Research Foundation
- Miles for Migraine
- National Headache Foundation
- Novartis AG
- Premera Blue Cross
- Society for Women’s Health Research
- Teva Pharmaceuticals
- UnitedHealthcare Services, Inc.
- US Pain Foundation